MTC was shown to decrease the number of triple positive CD133+/CD44+/CD24+ and CD44+ stem cells; however, its therapeutic implication has not been well defined yet [37, 38]. The gene discussed is PROM1; the disease is medullary thyroid gland carcinoma.